Marker Therapeutics - MRKR Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRKR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRKR, but not buy additional shares or sell existing shares.
View MRKR analyst ratings or view top-rated stocks.

1 brokerages have issued 1 year price objectives for Marker Therapeutics' shares. Their MRKR share price forecasts range from $1.00 to $1.50. On average, they predict the company's share price to reach $1.25 in the next twelve months. This suggests that the stock has a possible downside of 59.9%.
View analysts price targets for MRKR or view top-rated stocks among Wall Street analysts.

Marker Therapeutics' stock was trading at $0.2659 at the beginning of 2023. Since then, MRKR stock has increased by 1,072.2% and is now trading at $3.1170.
View the best growth stocks for 2023 here.

Marker Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 767,400 shares, an increase of 30.8% from the December 31st total of 586,600 shares. Based on an average daily trading volume, of 298,500 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.2% of the shares of the company are sold short.
View Marker Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our MRKR earnings forecast.

Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings results on Thursday, November, 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. The company earned $3.95 million during the quarter, compared to analyst estimates of $0.80 million. Marker Therapeutics had a negative net margin of 515.88% and a negative trailing twelve-month return on equity of 110.00%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Marker Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.30%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends.

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRKR stock can currently be purchased for approximately $3.12.

Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $26.06 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com.